Literature DB >> 17003370

STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90alpha and beta in multiple myeloma cells, which critically contribute to tumor-cell survival.

Manik Chatterjee1, Sarika Jain, Thorsten Stühmer, Mindaugas Andrulis, Ute Ungethüm, Ralf-Jürgen Kuban, Heike Lorentz, Kurt Bommert, Max Topp, Doris Krämer, Hans Konrad Müller-Hermelink, Hermann Einsele, Axel Greiner, Ralf C Bargou.   

Abstract

The combined blockade of the IL-6R/STAT3 and the MAPK signaling pathways has been shown to inhibit bone marrow microenvironment (BMM)-mediated survival of multiple myeloma (MM) cells. Here, we identify the molecular chaperones heat shock proteins (Hsp) 90alpha and beta as target genes of both pathways. The siRNA-mediated knockdown of Hsp90 or treatment with the novel Hsp90 inhibitor 17-DMAG attenuated the levels of STAT3 and phospho-ERK and decreased the viability of MM cells. Although knockdown of Hsp90beta-unlike knockdown of Hsp90alpha-was sufficient to induce apoptosis, this effect was strongly increased when both Hsp90s were targeted, indicating a cooperation of both. Given the importance of the BMM for drug resistance and MM-cell survival, apoptosis induced by Hsp90 inhibition was not mitigated in the presence of bone marrow stromal cells, osteoclasts, or endothelial cells. These observations suggest that a positive feedback loop consisting of Hsp90alpha/beta and major signaling pathways supports the survival of MM cells. Finally, in situ overexpression of both Hsp90 proteins was observed in most MMs but not in monoclonal gammopathy of undetermined significance (MGUS) or in normal plasma cells. Our results underpin a role for Hsp90alpha and beta in MM pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17003370     DOI: 10.1182/blood-2006-05-024372

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  62 in total

Review 1.  Apoptosis versus cell differentiation: role of heat shock proteins HSP90, HSP70 and HSP27.

Authors:  David Lanneau; Aurelie de Thonel; Sebastien Maurel; Celine Didelot; Carmen Garrido
Journal:  Prion       Date:  2007-01-24       Impact factor: 3.931

2.  Potent antitumor activity of HSP90 inhibitor AUY922 in adrenocortical carcinoma.

Authors:  Junchao Huang; Chengchao Sun; Ting Zhang; Lei Pan; Suqing Wang; Qiqiang He; Dejia Li
Journal:  Tumour Biol       Date:  2014-05-22

3.  Radiosensitizing effect of the novel Hsp90 inhibitor NVP-AUY922 in human tumour cell lines silenced for Hsp90α.

Authors:  L Stingl; N Niewidok; N Müller; M Selle; C S Djuzenova; M Flentje
Journal:  Strahlenther Onkol       Date:  2012-03-24       Impact factor: 3.621

Review 4.  Fever and the thermal regulation of immunity: the immune system feels the heat.

Authors:  Sharon S Evans; Elizabeth A Repasky; Daniel T Fisher
Journal:  Nat Rev Immunol       Date:  2015-05-15       Impact factor: 53.106

Review 5.  Preclinical studies of novel targeted therapies.

Authors:  Teru Hideshima; Kenneth C Anderson
Journal:  Hematol Oncol Clin North Am       Date:  2007-12       Impact factor: 3.722

6.  Role of calpastatin in the regulation of mRNA expression of calpain, caspase, and heat shock protein systems in bovine muscle satellite cells.

Authors:  Hoa Van Ba; Bandugula Venkata Reddy; Inho Hwang
Journal:  In Vitro Cell Dev Biol Anim       Date:  2014-12-09       Impact factor: 2.416

7.  Activation of Stat3 in renal tumors.

Authors:  Charles Guo; Guanyu Yang; Kyle Khun; Xiantian Kong; David Levy; Peng Lee; Jonathan Melamed
Journal:  Am J Transl Res       Date:  2009-02-28       Impact factor: 4.060

8.  The PI3K/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma.

Authors:  Manik Chatterjee; Mindaugas Andrulis; Thorsten Stühmer; Elisabeth Müller; Claudia Hofmann; Torsten Steinbrunn; Tanja Heimberger; Heike Schraud; Stefanie Kressmann; Hermann Einsele; Ralf C Bargou
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

9.  Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction.

Authors:  L Stingl; T Stühmer; M Chatterjee; M R Jensen; M Flentje; C S Djuzenova
Journal:  Br J Cancer       Date:  2010-05-25       Impact factor: 7.640

10.  Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance.

Authors:  Lei Shi; Siqing Wang; Maurizio Zangari; Hongwei Xu; Thai M Cao; Chunjiao Xu; Yong Wu; Fang Xiao; Yinghong Liu; Ye Yang; Mohamed Salama; Guiyuan Li; Guido Tricot; Fenghuang Zhan
Journal:  Oncotarget       Date:  2010-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.